Device Trial Radar · NCT07219745
Transanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS)
Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Case Comprehensive Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 22, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Transanal irrigation (TAI) has shown to improve fecal incontinence and increase quality of life in patients with low anterior resection syndrome (LARS). This trial is a small study being conducted to determine whether a larger trial is feasible. Investigators are also doing this research to see if TAI impacts quality of life and improves bowel function within the early post-operative period (1-12 months). This treatment is designed for participants to have more control over their bowel movements and reduce the dependency on immediate access to the toilet.
Conditions
- Colorectal Cancer
- Low Anterior Resection Syndrome
Interventions
Peristeen Plus Irrigation kitDevice
Transanal irrigation TAI is performed by inserting an applicator into the anal canal, inflating a balloon to occlude passage of stool and then installing 500-1000 mL of tap water via an irrigation system to fill the rectum and distal colon, followed by evacuation of bowel contents. Participants in the TAI-intervention arm will receive in-person training to learn how to use TAI and will also be given weekly virtual or in-person follow-up appointments for the first 4 weeks to troubleshoot any issues with TAI. Participants will do TAI once per day for 3 months. Each session of TAI takes about 20-60 minutes, depending on the individual's experience and bowel response.
LARS mobile applicationOther
Both arms will receive access to the LARS mobile application, which is a digital self-management tool. The app provides interactive educational content, personalized bowel function diaries, guided video tutorials, and peer testimonials, all designed to enhance engagement, promote self-efficacy, and support long-term self-management. The TAI-intervention arm will also receive access to a TAI Module on the LARS app that will offer comprehensive educational resources, including step-by-step guidance, animations, photographs, and participant videos to reinforce safe and confident use of the TAI system.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient-Reported Outcomes Measurement Information System (PROMIS)-GI Diarrhea at baselineTime frame: Baseline
- Patient-Reported Outcomes Measurement Information System (PROMIS)-GI Diarrhea at 1 monthTime frame: 1 month post randomization
- Patient-Reported Outcomes Measurement Information System (PROMIS)-GI Diarrhea at 2 monthsTime frame: 2 months post randomization
6 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Case Comprehensive Cancer Center, Digestive Disease Institute Cleveland Clinic Florida
Weston, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.